Cost-effectiveness of antiviral therapy during late pregnancy to prevent perinatal transmission of hepatitis B virus

PeerJ

Volumn 2016, Issue 3, 2016, Pages

  Wang, Wenjun ^a,b   Wang, Jingjing ^a   Dang, Shuangsuo ^a,b   Zhuang, Guihua ^b  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Cost effective; Hepatitis b virus; Lamivudine; Perinatal transmission; Pregnancy; Telbivudine; Tenofovir

Indexed keywords

LAMIVUDINE; TELBIVUDINE; TENOFOVIR;

ANTIVIRAL THERAPY; ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; FEMALE; HEPATITIS B; HUMAN; IMMUNOPROPHYLAXIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PERINATAL PERIOD; PREGNANCY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; VACCINATION; WORLD HEALTH ORGANIZATION;

EID: 84963988097     PISSN: None     EISSN: 21678359     Source Type: Journal    
DOI: 10.7717/peerj.1709     Document Type: Article

References (76)

1. Ayres A, Yuen L, Jackson KM, Manoharan S, Glass A, Maley M, Yoo W, Hong SP, Kim SO, Luciani F, Bowden DS, Bayliss J, Levy MT, Locarnini SA. 2014. Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations. Journal of Viral Hepatitis 21:809-817 DOI 10.1111/jvh.12212.
2. Bai HL, Shang HL, Li ZL. 2013. The clinical study of telbivudine in blocking intrauterine transmission of hepatitis B virus during late pregnancy. Zhong Guo Yi Xue Gong Cheng 21:53-54.
3. Brown Jr RS, Verna EC, Pereira MR, Tilson HH, Aguilar C, Leu CS, Buti M, Fagan EA. 2012. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. Journal of Hepatology 57:953-959 DOI 10.1016/j.jhep.2012.06.031.
4. Burgis J, Kong D, Salibay C, Zipprich J, Harriman K, So S. 2014. Risk factors associated with immunoprophylaxis failure in infants born to mothers with chronic hepatitis b infection in california [Abstract]. Gastroenterology 146:S-762.
5. Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP. 1994. Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. Journal of Infectious Diseases 170:1418-1423 DOI 10.1093/infdis/170.6.1418.
6. Buti M, Brosa M, Casado MA, Rueda M, Esteban R. 2009. Modeling the costeffectiveness of different oral antiviral therapies in patients with chronic hepatitis B. Journal of Hepatology 51:640-646 DOI 10.1016/j.jhep.2009.04.013.
7. Caldwell DM, Ades AE, Higgins JP. 2005. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 331:897-900 DOI 10.1136/bmj.331.7521.897.
8. Celen MK, Mert D, Ay M, Dal T, Kaya S, Yildirim N, Gulsun S, Barcin T, Kalkanli S, Dal MS, Ayaz C. 2013. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World Journal of Gastroenterology 19:9377-9382 DOI 10.3748/wjg.v19.i48.9377.
9. Chen D, Yao GB, Chen W. 2007. Economic evaluation of peginterferon afa-2a and lamivudine in the treatment of HBeAg-positive chronic hepatitis B. Chinese Journal of Clinical Infectious Diseases 25:468-472.
10. Chinese Center for Disease Control and Prevention. Prevention and treatment of viral hepatitis. Available at http://www.chinacdc.cn/rdwd/201107/t20110726_49934.htm (accessed 9 August 2013).
11. Chinese Society of Gynaecology and Obstetrics. 2013. The clinical guideline of prevention for mother-to-child transmission of hepatitis B virus. Zhong Hua Fu Chan Ke Za Zhi 48:151-154.
12. Chinese Society of Hepatology and Chinese Society of Infectious Diseases. 2011. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan Zang Bing Za Zhi 19:13-24.
13. Cui F, Luo H, Wang F, Zheng H, Gong X, Chen Y, Wu Z, Miao N, Kane M, Hennessey K, Hadler SC, Hutin YJ, Liang X, Yang W. 2013. Evaluation of policies and practices to prevent mother to child transmission of hepatitis B virus in China: results from China GAVI project final evaluation. Vaccine 31(Suppl 9):J36-J42 DOI 10.1016/j.vaccine.2012.11.061.
14. Del Canho R, Grosheide PM, Schalm SW, De Vries RR, Heijtink RA. 1994. Failure of neonatal hepatitis B vaccination: the role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates. Journal of Hepatology 20:483-486 DOI 10.1016/S0168-8278(05)80494-5.
15. European Association For The Study Of The Liver. 2012. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. Journal of Hepatology 57:167-185 DOI 10.1016/j.jhep.2012.02.010.
16. Fan L, Owusu-Edusei Jr K, Schillie SF, Murphy TV. 2014. Cost-effectiveness of testing hepatitis B-positive pregnant women for hepatitis B e antigen or viral load. Obstetrics and Gynecology 123:929-937 DOI 10.1097/AOG.0000000000000124.
17. Feng HF, Zhang SF. 2007. Effect on interruption of hepatitis B virus vertical transmission by lamivudine. Shi Yong Er Ke Lin Chuang Za Zhi 22:1019-1020.
18. Fontana RJ. 2009. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 49:S185-S195 DOI 10.1002/hep.22885.
19. Fung J, Seto WK, Lai CL, Yuen J, Wong DK, Yuen MF. 2011. Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: implications for antiviral therapy. Journal of Hepatology 54:195-200 DOI 10.1016/j.jhep.2010.06.031.
20. Gambarin-Gelwan M. 2007. Hepatitis B in pregnancy. Clinics in Liver Disease 11:945-963 DOI 10.1016/j.cld.2007.08.004.
21. Geisler BP. 2011. Automating firstand second-order Monte Carlo simulations for Markov models in TreeAge pro. In: Mordechai S, ed. Applications of Monte Carlo method in science and engineering. Shanghai: InTech, 917-930.
22. Guo YZ, Li SX, Ge SL, Wang JH. 2008. The clinical application of lamivudine in interdiction of maternal-to-child transmission for HBsAg, HBeAg-positive pregnant women. Lin Chuang He Li Yong Yao 1:8-9.
23. Guo Y, Liu J, Meng L, Meina H, Du Y. 2010. Survey of HBsAg-positive pregnant women and their infants regarding measures to prevent maternal-infantile transmission. BMC Infectious Diseases 10:26 DOI 10.1186/1471-2334-10-26.
24. Guo HJ, Zhang Y. 2011. The efficacy of telbivudine in interrupting mother-to-child HBV transmission in pregnant women with high levels of viremia. Chang Zhi Yi Xue Yuan Xue Bao 25:368-370.
25. Guo Y, Zhang W, Zhang Y, Lin X, Zhang B, Chen C, Du Y. 2012. Cost-effectiveness analysis of preventing mother-to-child transmission of hepatitis B by injecting hepatitis B immune globulin. European Journal of Gastroenterology & Hepatology 24:1363-1369 DOI 10.1097/MEG.0b013e32835847c6.
26. Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, Yue X, Wang GJ, Tang X, Fang ZX. 2011. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. Journal of Hepatology 55:1215-1221 DOI 10.1016/j.jhep.2011.02.032.
27. Han L, Zhang HW, Xie JX, Zhang Q, Wang HY, Cao GW. 2011. A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World Journal of Gastroenterology 17:4321-4333 DOI 10.3748/wjg.v17.i38.4321.
28. Ho A, Tran TT. 2011. Pregnant women and their willingness to be treated for hepatitis B during pregnancy [Abstract]. Gastroenterology 140:S930.
29. Hu M, Chen W. 2009. Assessment of total economic burden of chronic hepatitis B (CHB)-related diseases in Beijing and Guangzhou, China. Value Health 12(Suppl 3):S89-S92 DOI 10.1111/j.1524-4733.2009.00636.x.
30. Hu Y, Dai X, Zhou YH, Yang H. 2013. A knowledge survey of obstetrics and gynecology staffon the prevention of mother-to-child transmission of hepatitis B virus. Journal of Infection in Developing Countries 7:391-397 DOI 10.3855/jidc.2915.
31. Hung HF, Chen HH. 2011. Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection. PharmacoEconomics 29:1063-1073 DOI 10.2165/11586470-000000000-00000.
32. Hutton DW, So SK, Brandeau ML. 2010. Cost-effectiveness of nationwide hepatitis B catch-up vaccination among children and adolescents in China. Hepatology 51:405-414 DOI 10.1002/hep.23310.
33. Hu Y, Zhang S, Luo C, Liu Q, Zhou YH. 2012. Gaps in the prevention of perinatal transmission of hepatitis B virus between recommendations and routine practices in a highly endemic region: a provincial population-based study in China. BMC Infectious Diseases 12:221 DOI 10.1186/1471-2334-12-221.
34. Jiang HN, Fan LY, Li DZ, Wan J, Ye JJ. 2013. Clinical trial of telbivudine in the treatment of chronic hepatitis B in patients during the third trimester of pregnancy. Lin Chuang Gan Dan Bing Za Zhi 29:101-103.
35. Kangdele Pharmacy. 2014. Available at http://www.baiji.com.cn (accessed 16 October 2014).
36. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. 2005. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Annals of Internal Medicine 142:821-831 DOI 10.7326/0003-4819-142-10-200505170-00007.
37. Kubo A, Shlager L, Marks AR, Lakritz D, Beaumont C, Gabellini K, Corley DA. 2014. Prevention of vertical transmission of hepatitis B: an observational study. Annals of Internal Medicine 160:828-835 DOI 10.7326/M13-2529.
38. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA. 2007. Telbivudine versus lamivudine in patients with chronic hepatitis B. New England Journal of Medicine 357:2576-2588 DOI 10.1056/NEJMoa066422.
39. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. 2006. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database of Systematic Reviews 2006(2):CD004790 DOI 10.1002/14651858.CD004790.pub2.
40. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, Zhang Y, Liu J, Gong X, Chen Y, Wang F, Zheng H, Guo J, Jia Z, Ma J, Wang H, Luo H, Li L, Jin S, Hadler SC, Wang Y. 2009. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 27:6550-6557 DOI 10.1016/j.vaccine.2009.08.048.
41. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar D, Cooksley G, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano JD, Suh DJ, Omata M. 2012. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatology International 6:531-561 DOI 10.1007/s12072-012-9365-4.
42. Li XM, Yang YB, Hou HY, Shi ZJ, Shen HM, Teng BQ, Li AM, Shi MF, Zou L. 2003. Interruption of HBV intrauterine transmission: a clinical study. World Journal of Gastroenterology 9:1501-1503 DOI 10.3748/wjg.v9.i7.1501.
43. Lu YP, Liang XJ, Xiao XM, Huang SM, Liu ZW, Li J, Hocher B, Chen YP. 2014. Telbivudine during the second and third trimester of pregnancy interrupts HBV intrauterine transmission: a systematic review and meta-analysis. Clinical Laboratory 60:571-586.
44. Marcellin P, Heathcote EJ, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. 2008. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. New England Journal of Medicine 359:2442-2455 DOI 10.1056/NEJMoa0802878.
45. National Bureau of Statistics of China. 2013a. Available at http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.htm (accessed 9 August 2013).
46. National Bureau of Statistics of China. 2013b. Available at www.stats.gov.cn (accessed 9 August 2013).
47. National Health and Family Planning Commission of the People's Republic of China. 2013. China Public Health Statistical Yearbook 2011. Available at http://www.moh.gov.cn/zhuzhan/index.shtml (accessed 9 August 2013).
48. Nayeri UA, Werner EF, Han CS, Pettker CM, Funai EF, Thung SF. 2012. Antenatal lamivudine to reduce perinatal hepatitis B transmission: a cost-effectiveness analysis. American Journal of Obstetrics and Gynecology 207(3):231 DOI 10.1016/j.ajog.2012.06.001.
49. Ni YH, Huang LM, Chang MH, Yen CJ, Lu CY, You SL, Kao JH, Lin YC, Chen HL, Hsu HY, Chen DS. 2007. Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies. Gastroenterology 132:1287-1293 DOI 10.1053/j.gastro.2007.02.055.
50. Pan CQ, Duan ZP, Bhamidimarri KR, Zou HB, Liang XF, Li J, Tong MJ. 2012. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clinical Gastroenterology and Hepatology 10:452-459 DOI 10.1016/j.cgh.2011.10.041.
51. Pan CQ, Han GR, Jiang HX, Zhao W, Cao MK, Wang CM, Yue X, Wang GJ. 2012. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clinical Gastroenterology and Hepatology 10:520-526 DOI 10.1016/j.cgh.2012.01.019.
52. Pan CQ, Mi LJ, Bunchorntavakul C, Karsdon J, Huang WM, Singhvi G, Ghany MG, Reddy KR. 2012. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B virus infection by highly viremic pregnant women: a case series. Digestive Diseases and Sciences 57:2423-2429 DOI 10.1007/s10620-012-2187-3.
53. Patton H, Tran TT. 2014. Management of hepatitis B during pregnancy. Nature Reviews Gastroenterology & Hepatology 11:402-409 DOI 10.1038/nrgastro.2014.30.
54. Peng BA, Zhao Y, Yang XF, Liao MF, Xu LH, Yu YH. 2012. The efficacy and safety of telbivudine in blocking mother-to-child transmission of hepatitis B virus. Zhong Guo Yao Xue Za Zhi 47:855-857.
55. Price Bureau of Shaanxi Province. Available at www.sx111.com (accessed 9 August 2013).
56. Sarri G, Westby M, Bermingham S, Hill-Cawthorne G, Thomas H. 2013. Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance. BMJ 346:f3893 DOI 10.1136/bmj.f3893.
57. Shi G, Zhang SX. 2013. Decision tree and cost-benefit analysis on strategies related to preventing maternal-infantile transmission of hepatitis B virus infection. Zhonghua Liu Xing Bing Xue Za Zhi 34:273-278.
58. Stevens CE, Beasley RP, Tsui J, Lee WC. 1975. Vertical transmission of hepatitis B antigen in Taiwan. New England Journal of Medicine 292:771-774 DOI 10.1056/NEJM197504102921503.
59. Sun WH, Chu LL, Liu WL, Hao AH, Ma L, Wan Q, Ren R, Xin YN. 2013. Efficacy and safety of telbivudine in preventing mother-to-infant transmission of HBV in pregnant women in high HBV DNA load. Lin Chuang Gan Dan Bing Za Zhi 29:596-599.
60. Unal ER, Lazenby GB, Lintzenich AE, Simpson KN, Newman R, Goetzl L. 2011. Costeffectiveness of maternal treatment to prevent perinatal hepatitis B virus transmission. Obstetrics and Gynecology 118:655-662 DOI 10.1097/AOG.0b013e31822ad2c2.
61. Wang EJ. 2012. Comparision of effecacy and safety between lamivudine and telbivudine in blocking vertical transmission of hepatitis B virus in late stage pregnancy. Quan Ke Yi Shi Za Zhi 15:3628-3630.
62. Wang L, Kourtis AP, Ellington S, Legardy-Williams J, Bulterys M. 2013. Safety of tenofovir during pregnancy for the mother and fetus: a systematic review. Clinical Infectious Diseases 57:1773-1781 DOI 10.1093/cid/cit601.
63. Wang WP, Zhao J. 2012. The study of efficacy and side effects of telbivudine for treatment of patients with chronic hepatitis B in pregnant women. Xian Dai Fu Chan Ke Jin Zhan 21:697-699.
64. World Health Organization. 2013. Disease and injury country estimates, 2004-2008. Available at http://www.who.int/healthinfo/global_burden_disease/estimates_country_2004_2008/en (accessed 9 August 2013).
65. World Health Organization. 2014. Cost effectiveness and strategic planning (WHO-CHOICE). Available at http://www.who.int/choice/costs/en/(accessed 16 October 2014).
66. Wu QX, Deng GH, Li JN, Li L, Sun XW, Pan MM, Huang HF, He DM, Yan ZH, Xu C, Li MS, Tang W, Liu MD, Wang YM. 2013. Effects of telbivudine on transmission of HBsAg and HBeAg throught placenta in HBV infected pregnant women in second or third trimester. Di San Jun Yi Da Xue Xue Bao 35:665-668.
67. Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, Zhang SL, Qiao FY, Campbell F, Chang CN, Gardner S, Atkins M. 2009. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. Journal of Viral Hepatitis 16:94-103 DOI 10.1111/j.1365-2893.2008.01056.x.
68. Yao ZC, Chen MC, Liao WY, Zhang YP, Wu Y, Li LY, Feng J, Lin MS, Chen CA, Zheng DG, Zhuang JQ. 2011. The efficacy and safety of telbivudine in blocking intrauterine hepatitis B viral transmission. Shi Yong Gan Zang Bing Za Zhi 14:259-261.
69. Yi W, Liu M, Cai HD. 2012. Safety of lamivudine treatment for chronic hepatitis B in early pregnancy. World Journal of Gastroenterology 18:6645-6650 DOI 10.3748/wjg.v18.i45.6645.
70. Yu MM, Jiang Q, Ji Y, Wu KH, Ju LL, Tang X, Yang YF. 2014. Comparison of telbivudine versus lamivudine in interrupting perinatal transmission of hepatitis B virus. Journal of Clinical Virology 61:55-60 DOI 10.1016/j.jcv.2014.06.005.
71. Zeng YM, Chen R, Lou GQ, Shi JP. 2013. Study of the strategy about cessation of lamivudine used in HBV intrauterine infection. Yi Xue Yan Jiu Za Zhi 42:87-90.
72. Zhang YF. 2010. The effect of lamivudine on interruption of mother-to-child transmission in 50 pregnant women with chronic HBV infection. Shi Yong Fu Chan Ke Za Zhi 26:367-368.
73. Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. 2014. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology 60:468-475.
74. Zhang LJ, Wang L. 2009. Blocking intrauterine infection by telbivudine in pregnant chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi 17:561-563.
75. Zhao BD, Liao XQ, Peng GJ, Liu J, Lin CH. 2010. The efficacy of telbivudine combined with HBV vaccine and HBIG in interrupting mother-to-child transmission of HBV in 60 cases. Zhong Guo Xian Dai Yao Wu Ying Yong 4:37-38.
76. Zhou YJ, Zheng JL, Pan HJ, Jiang S. 2011. Efficacy and safety of telbivudine in pregnant chronic hepatitis B patients. Zhong Hua Gan Zang Bing Za Zhi 19:861-862.